Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment

Author:

Sahin Ahmet1,Caner Burcu2,Ocak Birol3,Gulmez Ahmet4,Hamitoglu Buket5,Cubukcu Erdem3,Deligonul Adem3,Orhan Sibel3,Canhoroz Mustafa6,Odman Hikmet3,Somali Isil5,Ocakoglu Gokhan7,Evrensel Turkkan3

Affiliation:

1. Department of Medical Oncology, School of Medicine, Usak University, Usak 64100, Turkey

2. Department of Medical Oncology, Atatürk City Hospital, Altieylul, Balıkesir 10100, Turkey

3. Department of Medical Oncology, School of Medicine, Uludag University, Nilufer, Bursa 16059, Turkey

4. Department of Medical Oncology, School of Medicine, Inonu University, Battalgazi, Malatya 44280, Turkey

5. Department of Medical Oncology, School of Medicine, Dokuz Eylul University, Konak, İzmir 35210, Turkey

6. Department of Medical Oncology, Bursa Medicana Hospital, Nilufer, Bursa 16110, Turkey

7. Department of Biostatistics, School of Medicine, Uludag University, Nilufer, Bursa 16059, Turkey

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3